Phostine 3.1a as a pharmacological compound with antiangiogenic properties against diseases with excess vascularization

What is it about?

We have investigated the effect of Phostine 3.1a (3-Hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl2-oxo-2λ5-[1,2]oxaphosphinane, PST 3.1a) on the formation of new blood vessels named angiogenesis required for tumor growth in an experimental model of glioblastoma. PST3.1a intervenes on all different step leading to the formation of blood vessels including migration, proliferation and adhesion of endothelial cells. Interestingly, PST3.1a reduced the formation of blood vessels in an experimental model of glioblastoma. This effect is due to its ability to modulate the interaction of two key proteins, vascular endothelial growth factor receptor 2 and galactin-1, important for metabolic process involved in vessel formation. These results provide information on an innovative approach to target angiogenesis-related diseases including cancer, which could eventually be extended to further diseases with excess vascularization. Most importantly, the present study underscores the potential use of PST 3.1a as new perspective in anti-angiogenic treatment of glyoblastoma.

Featured Image